About Ansa Biotechnologies
Ansa Biotechnologies makes synthetic DNA using an enzymatic method. Instead of the harsh chemicals used in conventional DNA synthesis, it attaches building blocks to a DNA-building enzyme, which the company says allows longer and more complex sequences. DNA synthesis matters for computing because synthetic DNA is the writing step in DNA data storage. Ansa sells its DNA as a service with guaranteed delivery times. In October 2025 it announced a $54.4 million Series B led by Cerberus Ventures, and its press release is datelined Emeryville, California.
Ansa Biotechnologies was founded in 2018 and is based in Emeryville, CA, United States. It is listed under DNA & Bio Computing. Reported funding is $54.4M Series B (Oct 2025).
Compute Technologies
- DNA & Bio Computing
What Ansa Biotechnologies works on
DNA & Bio Computing
Biocomputing uses biological material to store or process information. It has two main branches. DNA data storage encodes digital files in the four bases of DNA (A, C, G and T). Biological computing uses living cells or neurons grown in the lab as the computing element.
Also in United States
Iridia, Koniku, Ginkgo Bioworks, Catalog Technologies, Twist Bioscience
